Grifols Stock (NASDAQ:GRFS)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$8.46

52W Range

$5.30 - $12.15

50D Avg

$8.88

200D Avg

$7.75

Market Cap

$6.86B

Avg Vol (3M)

$1.14M

Beta

0.69

Div Yield

-

GRFS Company Profile


Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Show More

Industry

Drug Manufacturers - General

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

ES

Employees

23,000

IPO Date

Jun 02, 2011

Website

GRFS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Other Product€203.45M€250.16M€39.62M
Other diagnostic€21.79M€21.74M€23.63M
Transfusional medicine€648.48M€640.60M€712.24M
Bio supplies€159.96M€146.08M€225.76M
Haemoderivatives€5.56B€5.01B€3.81B
Fluid therapy and nutrition--€46.67M
Hospital supplies--€70.22M

Fiscal year ends in Dec 23 | Currency in EUR

GRFS Financial Summary


Dec 23Dec 22Dec 21
Revenue€6.59B€6.06B€4.93B
Operating Income€732.62M€805.68M€595.06M
Net Income€59.31M€208.28M€265.33M
EBITDA€1.11B€1.11B€955.39M
Basic EPS€0.09€0.31€0.39
Diluted EPS-€0.31€0.39

Fiscal year ends in Dec 23 | Currency in EUR

Latest Earnings Call Transcripts


Q1 24May 14, 24 | 12:00 AM
Q4 23Feb 29, 24 | 12:00 AM
Q3 23Nov 02, 23 | 10:33 PM

Peer Comparison


TickerCompany
AZNAstraZeneca PLC
BIIBBiogen Inc.
MRKMerck & Co., Inc.
GSKGSK plc
AMGNAmgen Inc.
BMYBristol-Myers Squibb Company
GILDGilead Sciences, Inc.
NVSNovartis AG
SNYSanofi